Since 3% mosaicism is arguably a very low level and probably uncommon in this setting, we suggest that this sensitivity will capture most (if not all) mosaic CAPS patients, since most reported mosaic NLRP3 mutation cases are 4.2–35.8% [6, 9, 40–43]. Here, NLRP3 is linked to cryopyrin-associated periodic syndrome.